EMA: AZD1222 causes serious rare ADEs
In a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis.
Targeting SARS-CoV-2 differently
German structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus main protease.
miRNAs unmask vulnerability in breast cancer stem cells
Researchers in Italy have identified a pair of microRNA molecules, miR-146A and miR-, help maintain a population of breast cancer stem cells
Janssen to pledge COVID-19 vaccine to African Union
Johnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).
Bispecific IgG switch off SARS-CoV-2 escape variants
A bispecific antibody designed by a Swiss-Czech research team suppressed viral escape of SARS-CoV-2 variants in animals.
Step Pharma SAS raises 35m in Series B
Kurma Partners-founded Step Pharma has baged 35m in a Series B financing to advance its blood cancer lead STP938.
AZD1222 claims 79% effecacy in pivotal US study
Following assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US.
EMA recommends to continue AZD1222 vaccinations
On Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine.
Novel COVID antibody enters clinical testing
German CORAT Therapeutics GmbH got the greenlight for Phase Ib/II testing of COR-101, an antibody that reduced virus load in the lung by more than 99 % within three days.
B.1.1.7 variant associated with higher mortality
The B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.